Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA - StreetInsider.com

Reuters India

Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA StreetInsider.com Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met ... Biogen pays Ionis $75 million to develop muscle drug after trial successReuters 15 Stocks Moving In Monday's Pre-Market SessionBenzinga Positive results halt Biogen, Ionis trial of SMA drugThe San Diego Union-Tribune all 5 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF6Pn3og46ouF_M3Mvmw5GlFIwN4A&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779170920455&ei=1kafV_CGN5TO3QG63oOYCA&url=http://www.streetinsider.com/Corporate%2BNews/Biogen%2B(BIIB),%2BIonis%2B(IONS)%2BAnnounce%2BNusinersen%2BPhase%2B3%2BMet%2BPrimary%2BEndpoint%2Bin%2BInfantile-Onset%2BSMA/11883808.html
via IFTTT